DB:CY71

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Anixa Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CY71's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.6%

CY71

-3.2%

DE Biotechs

-7.3%

DE Market


1 Year Return

-47.1%

CY71

-8.0%

DE Biotechs

-7.7%

DE Market

Return vs Industry: CY71 underperformed the German Biotechs industry which returned -6.3% over the past year.

Return vs Market: CY71 underperformed the German Market which returned -6.6% over the past year.


Shareholder returns

CY71IndustryMarket
7 Day-8.6%-3.2%-7.3%
30 Day-16.2%-15.4%-7.7%
90 Day-23.3%-14.5%-4.5%
1 Year-47.1%-47.1%-7.9%-8.0%-4.8%-7.7%
3 Yearn/a-5.3%-6.2%-9.2%-17.2%
5 Yearn/a36.1%34.5%11.4%-4.5%

Price Volatility Vs. Market

How volatile is Anixa Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Anixa Biosciences undervalued compared to its fair value and its price relative to the market?

5.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CY71's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CY71's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CY71 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: CY71 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CY71's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CY71 is overvalued based on its PB Ratio (5.7x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Anixa Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-24.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CY71 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CY71 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CY71 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CY71's revenue is forecast to grow faster than the German market.

High Growth Revenue: CY71 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CY71's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Anixa Biosciences performed over the past 5 years?

-24.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CY71 is currently unprofitable.

Growing Profit Margin: CY71 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CY71 is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.

Accelerating Growth: Unable to compare CY71's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CY71 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: CY71 has a negative Return on Equity (-122.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Anixa Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CY71's short term assets ($9.3M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: CY71's short term assets ($9.3M) exceed its long term liabilities ($10.6K).


Debt to Equity History and Analysis

Debt Level: CY71 is debt free.

Reducing Debt: CY71 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CY71 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CY71 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.1% each year.


Next Steps

Dividend

What is Anixa Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CY71's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CY71's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CY71's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CY71's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CY71's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Amit Kumar (56 yo)

3.25yrs

Tenure

US$665,490

Compensation

Dr. Amit Kumar, Ph.D. is the President and Chief Executive Officer at Anixa Biosciences, Inc since July 6, 2017 and has been its Chairman of the Board and Director since August 23, 2016 and November 30, 20 ...


CEO Compensation Analysis

Compensation vs Market: Amit's total compensation ($USD665.49K) is above average for companies of similar size in the German market ($USD483.38K).

Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Amit Kumar
Chairman3.25yrsUS$665.49k1.1%
$ 469.9k
Michael Catelani
COO, CFO & Corporate Secretary3.92yrsUS$313.02k0.025%
$ 10.5k
John Roop
Senior Vice President of Engineering8.08yrsUS$275.00kno data
Thomas Schlumpberger
Executive Vice President of Diagnostics1yrno datano data

3.6yrs

Average Tenure

56yo

Average Age

Experienced Management: CY71's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Amit Kumar
Chairman3.25yrsUS$665.49k1.1%
$ 469.9k
John Monahan
Independent Director4.17yrsUS$144.50k0.21%
$ 91.3k
Lewis Titterton
Lead Independent Director2.25yrsUS$144.50k4.29%
$ 1.8m
H. Shepard
Member of Scientific Advisory Boardno datano datano data
David Cavalier
Independent Director2.08yrsUS$144.50k0.0084%
$ 3.6k
Linda Kelley
Member of Scientific Advisory Board2yrsno datano data
Arnold Baskies
Member of Scientific Advisory Board & Independent Directorno dataUS$144.50k0.17%
$ 73.5k
Emanuele Ostuni
Member of Scientific Advisory Board1yrno datano data
Ian Frazer
Member of Scientific Advisory Board1yrno datano data
Marco Davila
Member of Scientific Advisory Board2yrsno datano data
Jose Conejo-Garcia
Member of Scientific Advisory Board2yrsno datano data
Daniel Abate-Daga
Member of Scientific Advisory Board2yrsno datano data

2.0yrs

Average Tenure

69yo

Average Age

Experienced Board: CY71's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CY71 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.7%.


Top Shareholders

Company Information

Anixa Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Anixa Biosciences, Inc.
  • Ticker: CY71
  • Exchange: DB
  • Founded: 1982
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$49.720m
  • Listing Market Cap: US$42.665m
  • Shares outstanding: 23.79m
  • Website: https://www.anixa.com

Number of Employees


Location

  • Anixa Biosciences, Inc.
  • 3150 Almaden Expressway
  • Suite 250
  • San Jose
  • California
  • 95118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANIXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 1983
CY71DB (Deutsche Boerse AG)YesCommon StockDEEUROct 1983

Biography

Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 21:43
End of Day Share Price2020/10/29 00:00
Earnings2020/07/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.